Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are two first-line pharmacological alternatives that are readily available. Tricyclic antidepressants and Monoamine Oxidase Inhibitors (MAOIs) are examples of second-line pharmacological alternatives (TCAs). Patients who are being treated frequently take other antidepressants or antipsychotics concurrently. The Major Depressive Disorder Treatment Market is divided into different treatment phases, such as the acute, continuation, and maintenance phases, but various forms of depression call for various regimens. Currently, pharmacotherapy, psychotherapy, or a combination of the two is used to treat the majority of MDD patients.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2022/11/major-depressive-disorder-treatment.html
